News & Media

Events
BIO Europe 2018

Read more
Events
Interim Report January - September 2018

Read more
Press release
Medivir appoints Dr. Linda Basse as Chief Medical Officer

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) announced today it has appointed Linda Basse as Chief Medical Officer effective October...

Read more
Press release
Investigator-initiated phase II clinical study of remetinostat started in patients with basal cell carcinoma

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announced that the first patient has been enrolled and is being dosed...

Read more
Press release
MIV-711 osteoarthritis phase IIa extension study outcomes show continuing positive effect on joint structure

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announces positive top-line joint structure outcomes from the MIV-711 osteoarthritis phase IIa...

Read more
Press release
MEDIVIR AB – INTERIM REPORT JANUARY – JUNE 2018

April – JuneSignificant events during the quarter Positive top-line results from the MIV-711 osteoarthritis phase IIa extension study. The study met...

Read more
Blog
Successful progression of clinical projects

On MIV-711, data from the initial phase IIa study demonstrating disease-modifying activity in patients with moderate knee osteoarthritis were presented by...

Read more
Press release
Medivir announces positive top-line results from the MIV-711 osteoarthritis phase IIa extension study

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announced positive top-line results from the MIV-711 phase IIa extension study (MIV-711-202)....

Read more
Press release
Continued discussions with FDA on proposed remetinostat phase III design results in delay in planned start of study

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announced that the Board of Directors have decided to continue the discussions...

Read more
Press release
Phase I/II study design of birinapant in combination with Keytruda® to be presented on June 4 at the ASCO Annual Meeting

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today informs that the design of the ongoing phase I/II study of birinapant...

Read more
Press release
Additional remetinostat phase II data will be presented at the International Investigative Dermatology meeting on May 18 and 19

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today informs that additional data from the phase II study of remetinostat in...

Read more
Press release
Resolutions at the Annual General Meeting in Medivir on 3 May 2018

Approval of profit and loss accounts and balance sheets, and discharge from liability of the board members and the managing directorThe...

Read more